SLAMF3/CD229 (E5E8A) Rabbit mAb #62759
- WB
- IP
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 120, 100 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
SLAMF3/CD229 (E5E8A) Rabbit mAb recognizes endogenous levels of total SLAMF3/CD229 protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to the intracellular domain of human SLAMF3/CD229 protein.
Background
Signaling lymphocytic activation molecule family 3 (SLAMF3/CD229) is a type-I transmembrane glycoprotein belonging to the SLAM family of immunoreceptors. Research studies have demonstrated that SLAMF3/CD229 is a homophilic, self-ligating receptor and expression is largely restricted to the surface of T cells and B cells (1,2). The extracellular domain of SLAMF3/CD229 contains a duplicated immunoglobulin (Ig)-like variable-type domain and a duplicated Ig-like C2-type domain, while the cytoplasmic domain is subject to alternative splicing and contains multiple potential tyrosine phosphorylation sites capable of recruiting signaling molecules such as EAT-2 and SAP (1,3,4). Research studies have shown that SLAMF3/CD229 is also highly overexpressed by multiple myeloma plasma cells and drives intracellular signaling cascades that promote plasma cell proliferation and survival (5-7).
- de la Fuente, M.A. et al. (2001) Blood 97, 3513-20.
- Romero, X. et al. (2005) J Immunol 174, 7033-42.
- Morra, M. et al. (2001) EMBO J 20, 5840-52.
- Sayós, J. et al. (2001) Blood 97, 3867-74.
- Ishibashi, M. et al. (2020) Mol Cancer Res 18, 632-643.
- Lin, Z. et al. (2022) Aging (Albany NY) 14, 9264-9279.
- Roncador, G. et al. (2022) Cancers (Basel) 14, 2154. doi: 10.3390/cancers14092154.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.